Urologists publish comment on GLP-1 agonists and erectile outcomes
The correspondence in the International Journal of Impotence Research responds to a paper on translating cardiometabolic benefits of incretin drugs into male sexual health.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 18 20:00 ETSource: International journal of impotence research
The wire
- 01Sellke and Eisenberg published a comment in the International Journal of Impotence Research on GLP-1 receptor agonists and male sexual health.
- 02Clinicians fielding questions about incretin therapy and erectile function are an audience for this exchange in the urology literature.
- 03The item is correspondence rather than new data; the underlying evidence base and any conclusions rest with the original article being discussed.
From the source
Read at pubmed.ncbi.nlm.nih.govComment on: GLP-1 receptor agonists and male sexual health: translating cardiometabolic benefits into erectile outcomes
International journal of impotence research · 2026 Oct 19 · Sellke N, Eisenberg ML et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42897274/
